Unjoni Ewropea -
Slovakk -
EMA (European Medicines Agency)
sabervel
pharmathen s.a. - irbesartan - vysoký tlak - Činidlá pôsobiace na systém renín-angiotenzín - sabervel je indikovaný u dospelých na liečbu esenciálnej hypertenzie. to je tiež indikovaný na liečbu ochorenia obličiek u dospelých pacientov s hypertenziou a diabetes mellitus 2. typu, ako súčasť antihypertensive lieku režim.
Slovakkja -
Slovakk -
Ústav štátnej kontroly veterinárnych biopreparátov a liečiv
castorex injekčná suspenzia pre králiky
pharmagal bio, slovenská republika - inj.
Unjoni Ewropea -
Slovakk -
EMA (European Medicines Agency)
abecma
bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastické činidlá - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.
Unjoni Ewropea -
Slovakk -
EMA (European Medicines Agency)
breyanzi
bristol-myers squibb pharma eeig - cd19-directed genetically modified autologous cell-based product consisting of purified cd8+ t-cells (cd8+ cells), cd19-directed genetically modified autologous cell-based product consisting of purified cd4+ t cells (cd4+ cells) - lymphoma, large b-cell, diffuse; lymphoma, follicular; mediastinal neoplasms - antineoplastické činidlá - breyanzi is indicated for the treatment of adult patients with diffuse large b-cell lymphoma (dlbcl), high grade b-cell lymphoma (hgbcl), primary mediastinal large b-cell lymphoma (pmbcl) and follicular lymphoma grade 3b (fl3b), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Unjoni Ewropea -
Slovakk -
EMA (European Medicines Agency)
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - viacnásobný myelóm - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
Slovakkja -
Slovakk -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
albutein 200 g/l
instituto grifols, s.a., Španielsko - albumín - 59 - immunopraeparata
Slovakkja -
Slovakk -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
marcaine 0,25 %
aspen pharma trading limited, Írsko - bupivakaín - 01 - anaesthetica (lokÁlne)
Slovakkja -
Slovakk -
ŠÚKL (Štátny ústav pre kontrolu liečiv)
sanergy spinal 5 mg/ml injekčný roztok
as grindeks, lotyšsko - bupivakaín - 01 - anaesthetica (lokÁlne)